Health & Beauty

Recently, the National Health Commission and other departments jointly issued relevant opinions to further strengthen the work of Chinese medicine in general hospitals and promote the coordinated development of Chinese and Western medicine in general hospitals. In recent years, with the continuous implementation of Chinese medicine-related policies, the Chinese medicine industry has ushered in a new round of business cycle. Look at the reporter's report.

The reporter learned from a Chinese medicine hospital in Shenzhen that since the outbreak of the new crown epidemic last year, the number of Chinese medicine outpatients in the hospital has increased significantly. Zhang Tianfeng, secretary of the Party Committee of Shenzhen Hospital of Guangzhou University of Chinese Medicine, said that the number of outpatient visits in the hospital this year has increased significantly, mainly in our internal medicine system, as well as in the rehabilitation system. Compared with last year, the average increase in 2021 and 2020 will be 15% to 20%.

"Patchouli was also sold in 2019 at least. The original statistics were from 12.000 yuan to 13.000 yuan per ton. Now it has exceeded 19.000 yuan to 20,000 yuan. This patchouli is very obvious. We Morinda The same is true for the sky, and the same for cinnamon.". Liang Zhan is the person in charge of a Chinese medicinal material planting management company in Zhaoqing City, Guangdong Province. The company he works for is mainly engaged in the cultivation, processing and sales of Chinese medicinal materials. He told reporters that since the rise of Chinese medicine fever, the medicinal materials operated by his company have not only increased in sales, but also in prices.

The increase in market demand for Chinese medicinal materials means the arrival of a new economic cycle for the entire Chinese medicine industry. According to the "2019-2021 China Traditional Chinese Medicine Industry Development Status and Industry Chain Analysis Report" released by iiMedia Consulting, the market size of China's traditional Chinese medicine industry reached nearly 124.6 billion yuan in 2018, and it is expected to reach 170.8 billion yuan in 2022. Compound growth of nearly 10%. In addition, in the past two years, the central and local governments have successively issued a number of relevant policies to implement the development of the Chinese medicine industry. The favorable policies have also stimulated the development of the Chinese medicine industry. Lin Rui, Director of the Taxation Bureau of Zhuhai Jinwan District, State Administration of Taxation, said that Chinese medicine companies with R&D investment can not only enjoy the preferential tax deduction policy for R&D expenses, but also can be levied at a reduced tax rate of 15% as long as they meet the qualifications of high-tech enterprises. corporate income tax.